Next Article in Journal
Chitosan-Based Composite Materials for Prospective Hemostatic Applications
Next Article in Special Issue
Antimicrobial and Antibiofilm Activity of a Recombinant Fragment of β-Thymosin of Sea Urchin Paracentrotus lividus
Previous Article in Journal
Chemical Mutagenesis and Fluorescence-Based High-Throughput Screening for Enhanced Accumulation of Carotenoids in a Model Marine Diatom Phaeodactylum tricornutum
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 16
Issue 8
10.3390/md16080274
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

New Thiazole Nortopsentin Analogues Inhibit Bacterial Biofilm Formation

by
Anna Carbone
,
Barbara Parrino
,
Maria Grazia Cusimano
,
Virginia Spanò
,
Alessandra Montalbano
,
Paola Barraja
,
Domenico Schillaci
,
Girolamo Cirrincione
,
Patrizia Diana
* and
Stella Cascioferro
Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90100 Palermo, Italy
*
Author to whom correspondence should be addressed.
Mar. Drugs 2018, 16(8), 274; https://doi.org/10.3390/md16080274
Submission received: 21 June 2018 / Revised: 23 July 2018 / Accepted: 24 July 2018 / Published: 4 August 2018
(This article belongs to the Special Issue New Strategies to Counteract Antibiotic Resistance Mechanisms)
Browse Figures
Versions Notes

Abstract

:
New thiazole nortopsentin analogues were conveniently synthesized and evaluated for their activity as inhibitors of biofilm formation of relevant Gram-positive and Gram-negative pathogens. All compounds were able to interfere with the first step of biofilm formation in a dose-dependent manner, showing a selectivity against the staphylococcal strains. The most active derivatives elicited IC50 values against Staphylococcus aureus ATCC 25923, ranging from 0.40–2.03 µM. The new compounds showed a typical anti-virulence profile, being able to inhibit the biofilm formation without affecting the microbial growth in the planktonic form.

Graphical Abstract

1. Introduction

Antibiotic resistance has become a severe global health risk, and this is partly due to excessive use of antimicrobial agents. It is estimated that in the United States alone, more than 2 million people per year are infected by antibiotic-resistant pathogens. Drug-resistant infections lead to about 23,000 deaths in the United States and 25,000 in Europe every year, and the number is higher in developing countries [1,2].
About 60–80% of bacterial infections are biofilm-mediated [3]. Biofilms are surface-attached microbial communities encased within an extracellular self-synthesized matrix able to grow both on different biotic or abiotic surfaces as indwelling devices. The biofilm architecture allows the microbes to survive in adverse conditions and it makes bacterial cells 1000 times more resistant to conventional antibiotics than the planktonic form of life of the same strains [4]. At cellular level, bacteria can develop three major mechanisms to make conventional antibiotic treatments ineffective: (i) enzymatic resistance, such as the production of β-lactamases; (ii) structural changes in the antibiotic target; and (iii) modifications in cell permeability, for example by efflux pumps. Bacterial cells in biofilm, besides these resistance mechanisms, have additional defenses because they are protected by the matrix, which prevents the entry of antibiotics, and the deepest layers undergo a metabolic inactivation that lead to the formation of dormant persister cells naturally resistant to most antibiotics.
Biofilms are responsible for a wide range of serious chronic diseases such as endocarditis, otitis media, periodontitis, prostatitis, and urinary infections. Several bacteria, including Gram-positive pathogens such as Staphylococcus aureus, Streptococcus pneumoniae and Gram-negative pathogens such as Escherichia coli, and Pseudomonas aeruginosa are often the causes of biofilm-associated infections, which are extremely challenging to treat [5].
Despite many efforts having been made in the last few years and several compounds being reported as antibiofilm agents [6,7,8,9], no derivative has reached clinical use. Therefore, there is an urgent need for the development of new therapeutic strategies effective in inhibiting biofilm formation or in dispersing preformed biofilm.
The marine environment is an important source of secondary metabolites endowed with antimicrobial activity. In particular, marine sponges are a rich source of antibacterial compounds with different mode of action. Dihydrosventrin and sventrin, bromopyrrole alkaloids, isolated from marine sponges, are biofilm inhibitors at 51 and 74 µM against P. aeruginosa [10]. The 2-aminoimidazole oroidin, a marine alkaloid, isolated from the marine sponge Agelas conifer, and its analogues are studied for antibiofilm activity [11]. Sortase A (SrtA), a transpeptidase involved in the anchoring of surface proteins to the Gram-positive bacterial cell wall, plays a key role in bacterial adhesion, immune evasion and biofilm formation [12,13]. 1H-Benzo[de][1,6]-naphthyridine alkaloid isoaaptamine, isolated from the marine sponge Aaptos aaptos [14], was reported to be a potent inhibitor of SrtA (IC50 value of 3.7 µM). Topsentins and hamacanthins are representative examples of marine-derived compounds displaying SrtA inhibitory activity, in particular deoxytopsentin and 6′′-debromohamacanthin A, bis(indole)alkaloids isolated from the marine sponge Spongosorites sp., showed IC50 values of 15.67 µM and 34.04 µM, respectively [15].
In the framework of our research on polycyclic nitrogen systems, [16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33] particularly referring to nortopsentin alkaloid analogues [34,35,36,37,38,39], herein we report the synthesis of the new series of thiazoles 1 (Table 1) and their evaluation as antibiofilm agents. In this series of nortopsentin analogues, the imidazole core of the natural product is replaced by the thiazole ring and one of the indole units is replaced by a 7-aza-indole moiety decorated with an ethanamine chain bound to the imine nitrogen. The evaluation as antibiofilm agents was performed on both the new thiazoles 1 and their N-2-methoxyethyl analogues 2 (Table 2), previously reported by us as antitumor agents [39], against three bacterial reference strains: S. aureus ATCC 25923, S. aureus ATCC 6538 and P. aeuruginosa ATCC 15442.

2. Results and Discussion

2.1. Chemistry

Thiazoles of type 1 were conveniently prepared by Hantzsch reaction between thioamides 6a–d and α-bromoacetyl compounds 7a,b (Scheme 1). Indole-3-carbothioamides 6a–d were obtained from the corresponding tert-butyl [2-(3-cyano-1H-indol-1-yl)ethyl]carbamates 5a–d, easily prepared (61–82%) by reaction of the corresponding carbonitriles 4a–d with tert-butyl (2-bromoethyl)carbamate using N,N-dimethylformamide (DMF) as solvent and sodium hydride as base. Carbonitriles 4a–d were synthesized (90–98%) from the commercially available indoles 3a–d, which were reacted with chlorosulfonyl isocyanate (CSI) in acetonitrile, followed by the addition of N,N-dimethylformamide (DMF). The reaction of carbonitriles 5a–d with phosphorus pentasulfide (P4S10), under reflux in ethanol, gave the desired thioamides 6a–d in good yields (60–72%). α-Bromoacetyl compounds 7a,b were obtained as previously reported by us [40]. The reaction of thioamides of type 6 with α-bromoacetyl compounds 7a,b, in ethanol under reflux, gave the desired thiazoles 1a–h (61–87%). Their subsequent deprotection using trifluoacetic acid (TFA) in refluxing dichoromethane (DCM) led, after neutralization, to the corresponding thiazoles 1i–p (60–91%) (Table 1).
The reaction of thioamides 6c,d with the 3-bromoacetyl derivative 7a gave very unstable compounds that were used for the next step without purification.

2.2. Biology

The new synthesized thiazoles 1 and their previously described N-2-methoxyethyl analogues of type 2 were tested against S. aureus ATCC 25923, S. aureus ATCC 6538 and P. aeuruginosa ATCC 15442 to evaluate their ability to inhibit biofilm formation and microbial growth.
All new compounds were preliminarily assayed against the planktonic form and they did not affect the microbial growth, showing Minimum Inhibitory Concentrations (MIC) values greater than 100 µg/mL.
Inhibition of biofilm formation of reference staphylococcal strains and P. aeruginosa was evaluated at sub-MIC concentrations, and IC50 values were determined and reported in Table 3. All tested thiazole derivatives, except 2l and 2o, were active as inhibitors of staphylococcal biofilm formation of both reference strains. Compounds 1p, 2i, 2j, and 2n were the most active against S. aureus ATCC 25923, eliciting IC50 values of 1.2 µM (0.5 µg/mL), 1.7 µM (0.79 µg/mL), 2.0 µM (0.95 µg/mL) and 0.4 µM (0.2 µg/mL), respectively.
Compounds 1a and 2r showed the best selectivity against staphylococcal biofilm formation as they showed IC50 values against S. aureus ATCC 25923 of 8.4 µM (2.9 µg/mL) and 3.7 µM (1.8 µg/mL), respectively, without affecting P. aeruginosa biofilm formation. The thiazole derivatives of the series 1 were more active than those of the series 2 in inhibiting Gram-negative biofilm formation. The highest potency against P. aeruginosa was observed for 1p whose IC50 value was 9.9 µM (3.9 µg/mL). In the series 2, only 2i was able to inhibit pseudomonal biofilm formation, showing an IC50 value of 9.7 µM (4.4 µg/mL).
All the compounds were also tested, at the screening concentration of 100 µg/mL, for their dispersal activity against the preformed staphylococcal biofilm, but none were able to disrupt biofilm architecture.
Considering that most of the synthesized compounds were selective towards Gram-positive biofilms, we selected the most potent inhibitors of staphylococcal biofilm formation, 1a and 2r, for further studies to elucidate the possible mechanism of action. First, we hypothesized a possible interference with the transpeptidase activity of the enzyme SrtA. A screening concentration of 100 µM 1a showed an inhibition of 47.8%, whereas 2r, despite its higher potency against the biofilm formation, was inactive (Figure 1).
Even if 1a was able to inhibit SrtA activity, further studies on the anti-adhesion mechanism of action are needed. However, the new compounds showed an interesting anti-virulence behavior being capable of interfering with the biofilm formation process, which represents one of the most relevant virulence factors of many pathogens, without affecting microbial viability and imposing a low selective pressure for the evolution of antibiotic resistance mechanisms.

3. Materials and Methods

3.1. Chemistry

3.1.1. General

All melting point were taken on a Büchi-Tottoly capillary apparatus (Büchi, Cornaredo, Italy) and are uncorrected. IR spectra were determined in bromoform with a Shimadzu FT/IR 8400S spectrophotometer (Shimadzu Corporation, Milan, Italy). 1H and 13C NMR spectra were measured at 200 and 50.0 MHz, respectively, in DMSO-d6 solution, using a Bruker Avance II series 200 MHz spectrometer (Bruker, Milan, Italy). Column chromatography was performed with Merk silica gel 230–400 mesh ASTM (Sigma Aldrich, Milan, Italy) or with Büchi Sepacor chromatography module (prepacked cartridge system) (Büchi, Cornaredo, Italy). Elemental analyses (C, H, N) were within ±0.4% of theoretical values and were performed with a VARIO EL III elemental analyzer (Elementar, Langenselbold, Germany). Purity of all the tested compounds was greater than 95%, determined by HPLC (Agilent 1100 Series) (Agilent Technologies, Milan, Italy).

3.1.2. General Procedure for the Synthesis of 1H-Indole-3-carbonitriles (4a–d)

To a solution of the appropriate indoles 3a–d (6.8 mmol) in anhydrous acetonitrile (6.0 mL), chlorosulfonyl isocyanate (CSI) (0.63 mL, 7.25 mmol) was added dropwise at 0 °C and the reaction mixture was stirred at 0 °C for 2 h. Anhydrous dimethylformamide (DMF) (1.3 mL, 170.0 mmol) was added dropwise and the mixture was stirred at 0 °C for 2 h. The mixture was poured into ice-water and the obtained precipitate was filtered off, dried (anhydrous Na2SO4) and purified by column chromatography using petroleum ether/ethyl acetate (40/60) (for 4b–d) or ethyl acetate (for 4a) as eluent.
1H-In.dole-3-carbonitrile (4a)
White solid; yield: 96%; mp: 181 °C; spectroscopic data are in accordance with those reported in literature [41].
5-Met.hoxy-1H-indole-3-carbonitrile (4b)
White solid; yield: 90%; mp: 157 °C; spectroscopic data in accordance with those reported in literature [41].
5-Bro.mo-1H-indole-3-carbonitrile (4c)
White solid; yield: 91%; mp: 193 °C; IR cm−1: 2219 (CN), 3440 (NH); 1H NMR (200 MHz, DMSO-d6) δ: 7.42 (dd, 1H, J = 8.7, 1.8 Hz, H-6), 7.54 (d, 1H, J = 8.7 Hz, H-7), 7.81 (d, 1H, J = 1.8 Hz, H-4), 8.33 (s, 1H, H-2), 12.42 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 83.9 (C), 114.4 (C), 115.0 (CH), 115.7 (C), 120.7 (CH), 126.1 (CH), 128.4 (C), 134.0 (CN), 135.9 (CH). Anal. Calcd. for: C9H5BrN2: C, 48.90; H, 2.28; N, 12.67. Found: C, 48.74; H, 2.44; N, 12.93.
5-Flu.oro-1H-indole-3-carbonitrile (4d)
White solid; yield: 98%; mp: 182 °C; spectroscopic data in accordance with those reported in literature. [41]

3.1.3. General Procedure for the Synthesis of Tert-Butyl [2-(3-cyano-1H-indol-1-yl)ethyl]carbamates (5a–d)

To a cold solution of the appropriate indoles 4a–d (4.2 mmol) in anhydrous DMF (7.8 mL) NaH (60% suspension in mineral oil, 6.3 mmol, 0.25 g) was added. After 30 min stirring at room temperature, tert-butyl (2-bromoethyl)carbamate [42] (6.3 mmol, 1.4 g) was added. The reaction mixture was heated at 60 °C for 24 h. After cooling, the mixture was poured into ice-water and extracted with ethyl acetate (3 × 20 mL). The organic phases were dried (anhydrous Na2SO4) and evaporated under reduced pressure. The residue was purified by column chromatography using petroleum ether/ethyl acetate (70/30) (for 5b–d) or petroleum ether/ethyl acetate (50/50) (for 5a) as eluent.
Tert-Butyl [2-(3-cyano-1H-indol-1-yl)ethyl]carbamate (5a)
White solid; yield: 80%; mp: 143 °C; IR cm−1: 3335 (NH), 2220 (CN), 1706 (CO); 1H NMR (200 MHz, DMSO-d6) δ: 1.30 (s, 9H, 3 × CH3), 3.28–3.36 (m, 2H, CH2), 4.30 (t, 2H, J = 5.8 Hz, CH2), 6.98 (t, 1H, J = 5.6 Hz, NH), 7.23–7.38 (m, 2H, H-5 and H-6), 7.63–7.67 (m, 2H, H-4 and H-7), 8.21 (s, 1H, H-2); 13C NMR (50 MHz, DMSO-d6) δ: 28.0 (3 × CH3), 40.0 (CH2), 45.9 (CH2), 77.8 (C), 83.6 (C), 111.4 (CH), 116.1 (C), 118.6 (CH), 121.8 (CH), 123.3 (CH), 127.1 (C), 135.6 (CN), 137.0 (CH), 155.5 (CO). Anal. Calcd. for: C16H19N3O2: C, 67.35; H, 6.71; N, 14.73. Found: C, 67.28; H, 6.89; N, 14.90.
Tert-Butyl [2-(5-methoxy-3-cyano-1H-indol-1-yl)ethyl]carbamate (5b)
White solid; yield: 61%; mp: 149 °C; IR cm−C1: 3382 (NH), 2212 (CN), 1703 (CO); 1H NMR (200 MHz, DMSO-d6) δ: 1.31 (s, 9H, 3 × CH3), 3.26–3.36 (m, 2H, CH2), 3.82 (s, 3H, CH3), 4.25 (t, 2H, J = 5.6 Hz, CH2), 6.92–7.00 (m, 2H, H-6 and NH), 7.08 (d, 1H, J = 2.2 Hz, H-4), 7.55 (d, 1H, J = 9.0 Hz, H-7), 8.12 (s, 1H, H-2); 13C NMR (50 MHz, DMSO-d6) δ: 28.0 (3 × CH3), 40.0 (CH2), 46.0 (CH2), 55.4 (CH3), 77.8 (C), 83.4 (C), 100.0 (CH), 112.3 (CH), 113.6 (CH), 116.3 (C), 127.9 (C), 130.4 (C), 136.8 (CH), 155.4 (CN), 155.5 (CO). Anal. Calcd. for: C17H21N3O3: C, 64.74; H, 6.71; N, 13.32. Found: C, 64.63; H, 6.95; N, 13.57.
Tert-Butyl [2-(5-bromo-3-cyano-1H-indol-1-yl)ethyl]carbamate (5c)
White solid; yield: 82%; mp: 183 °C; IR cm−1: 3356 (NH), 2221 (CN), 1684 (CO); 1H NMR (200 MHz, DMSO-d6) δ: 1.26 (s, 9H, 3 × CH3), 3.26–3.40 (m, 2H, CH2), 4.29 (t, 2H, J = 5.6 Hz, CH2), 6.96 (t, 1H, J = 5.8 Hz, NH), 7.48 (dd, 1H, J = 8.8, 2.0 Hz, H-6), 7.64 (d, 1H, J = 8.8 Hz, H-7), 7.80 (d, 1H, J = 2.0 Hz, H-4), 8.26 (s, 1H, H-2); 13C NMR (50 MHz, DMSO-d6) δ: 27.4 (3 × CH3), 39.9 (CH2), 46.3 (CH2), 77.8 (C), 83.3 (C), 113.6 (CH), 114.6 (C), 115.4 (C), 120.9 (CH), 126.0 (CH), 128.7 (C), 134.5 (CO), 138.4 (CH), 155.4 (CN). Anal. Calcd. for: C16H18BrN3O2: C, 52.76; H, 4.98; N, 11.54. Found: C, 52.61; H, 5.24; N, 11.67.
Tert-Butyl [2-(5-fluoro-3-cyano-1H-indol-1-yl)ethyl]carbamate (5d)
White solid; yield: 65%; mp: 182 °C; IR cm−1: 3357 (NH), 2221 (CN), 1701 (CO); 1H NMR (200 MHz, DMSO-d6) δ: 1.28 (s, 9H, 3 × CH3), 3.30–3.35 (m, 2H, CH2), 4.29 (t, 2H, J = 5.1 Hz, CH2), 6.97 (t, 1H, J = 6.0 Hz, NH), 7.22 (td, 1H, J = 11.4, 9.2, 2.3 Hz, H-6), 7.43 (dd, 1H, J = 11.4, 2.3 Hz, H-4), 7.69 (dd, 1H, J = 9.2, 4.2 Hz, H-7), 8.27 (s, 1H, H-2); 13C NMR (50 MHz, DMSO-d6) δ: 77.8 (C), 83.8 (C, JC7a-F = 4.2 Hz), 103.9 (CH, JC6-F = 24.6 Hz), 111.7 (CH, JC4-F = 26.2 Hz), 112.8 (C), 113.0 (CH, JC7-F = 9.5 Hz), 115.6 (C), 127.6 (C, JC3a-F = 11.0 Hz), 132.3 (C), 138.6 (CH), 158.5 (C, JC5-F = 238 Hz). Anal. Calcd. for: C16H18FN3O2: C, 63.35; H, 5.98; N, 13.85. Found: C, 63.18; H, 6.14; N, 13.67.

3.1.4. General Procedure for the Synthesis of Tert-Butyl [2-(3-carbamothioyl-1H-indol-1-yl)ethyl]carbamate (6a–d)

A solution of phosphorus pentasulfide (P4S10) (0.73 g, 1.64 mmol) in anhydrous ethanol (2.0 mL) was stirred at room temperature for 1 h. The appropriate indole carbonitriles 5a–d (0.3 g, 0.82 mmol) was added and the reaction mixture was heated under reflux for 24 h. Water (20 mL) was added and the reaction mixture was extracted with ethyl acetate (3 × 20 mL). The organic phases were dried (anhydrous Na2SO4) and evaporated under reduced pressure. The residue was purified by column chromatography using dichloromethane/ethyl acetate (70:30) as eluent.
Tert-Butyl [2-(3-carbamothioyl-1H-indol-1-yl)ethyl]carbamate (6a)
Yellow solid; yield: 60%; mp: 162 °C; IR cm−1: 3389 (NH), 3375, 3448 (NH2), 1707 (CO), 1595 (CS); 1H NMR (200 MHz, DMSO-d6) δ: 1.35 (s, 9H, 3 × CH3), 3.30–3.36 (m, 2H, CH2), 4.26 (t, 2H, J = 5.9 Hz, CH2), 7.02 (t, 1H, J = 5.4 Hz, NH), 7.14–7.27 (m, 2H, H-5 and H-6), 7.50–7.55 (m, 1H, H-7), 8.09 (s, 1H, H-2), 8.57 (d, 1H, J = 6.8 Hz, H-4), 8.78 (bs, 1H, SH), 9.00 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 27.4 (3 × CH3), 40.1 (CH2), 45.3 (CH2), 77.9 (C), 110.3 (CH), 115.8 (C), 121.0 (CH), 121.8 (CH), 122.1 (CH), 126.0 (C), 131.9 (CH), 136.5 (C), 155.6 (CO), 193.1 (CS). Anal. Calcd. for: C16H21N3O2S: C, 60.16; H, 6.63; N, 13.16. Found: C, 60.02; H, 6.89; N, 13.40.
Tert-Butyl [2-(3-carbamothioyl-5-methoxy-1H-indol-1-yl)ethyl]carbamate (6b)
Yellow solid; yield: 72%; mp: 172 °C; IR cm−1: 3382 (NH), 3265, 3178 (NH2), 1688 (CO), 1525 (CS); 1H NMR (200 MHz, DMSO-d6) δ: 1.35 (s, 9H, 3 × CH3), 3.25–3.33 (m, 2H, CH2), 3.79 (s, 3H, CH3), 4.22 (t, 2H, J = 5.8 Hz, CH2), 6.87 (dd, 1H, J = 8.9, 2.5 Hz, H-6), 7.01 (t, 1H, J = 5.5 Hz, NH), 7.42 (d, 1H, J = 8.9 Hz, H-7), 8.06 (s, 1H, H-2), 8.17 (d, 1H, J = 2.5 Hz, H-4), 8.73 (s, 1H, SH), 8.93 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 28.1 (3 × CH3), 40.3 (CH2), 45.5 (CH2), 55.3 (CH3), 77.9 (C), 103.9 (CH), 111.1 (CH), 111.8 (CH), 115.2 (C), 126.7 (C), 131.9 (C), 132.2 (CH), 154.9 (C), 155.6 (CO), 192.9 (CS). Anal. Calcd. for: C17H23N3O3S: C, 58.43; H, 6.63; N, 12.02. Found: C, 58.19; H, 6.37; N, 11.75.
Tert-Butyl [2-(3-carbamothioyl-5-bromo-1H-indol-1-yl)ethyl]carbamate (6c)
Yellow solid; yield: 72%; mp: 172 °C; IR cm−1: 3278 (NH), 3402, 3371 (NH2), 1684 (CO), 1533 (CS); 1H NMR (200 MHz, DMSO-d6) δ: 1.32 (s, 9H, 3 × CH3), 3.28-3.37 (m, 2H, CH2), 4.25 (t, 2H, J = 5.5 Hz, CH2), 7.01 (t, 1H, J = 5.5 Hz, NH), 7.36 (dd, 1H, J = 8.7, 1.9 Hz, H-6), 7.52 (d, 1H, J = 8.7 Hz, H-7), 8.13 (s, 1H, H-2), 8.87 (d, 1H, J = 1.9 Hz, H-4), 8.91 (s, 1H, SH), 9.08 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 28.1 (3 × CH3), 40.0 (CH2), 45.7 (CH2), 77.9 (C), 112.5 (CH), 114.0 (C), 115.9 (C), 124.1 (CH), 124.6 (CH), 128.1 (C), 132.3 (CH), 135.7 (C), 155.6 (CO), 192.5 (CS). Anal. Calcd. for: C16H20BrN3O2S: C, 48.25; H, 5.06; N, 10.55. Found: C, 48.13; H, 4.95; N, 10.68.
Tert-Butyl [2-(3-carbamothioyl-5-fluoro-1H-indol-1-yl)ethyl]carbamate (6d)
Yellow solid; yield: 60%; mp: 166 °C; IR cm−1: 3374 (NH), 3278, 3182 (NH2), 1686 (CO), 1526 (CS);1H NMR (200 MHz, DMSO-d6) δ: 1.33 (s, 9H, 3 × CH3), 3.29–3.37 (m, 2H, CH2), 4.26 (t, 2H, J = 5.8 Hz, CH2), 6.99-7.14 (m, 2H, H-6 and NH), 7.55 (dd, 1H, J = 9.0, 4.6 Hz, H-7), 8.16 (s, 1H, H-2), 8.42 (dd, 1H, J = 11.0, 2.5 Hz, H-4), 8.85 (bs, 1H, SH), 9.03 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 28.1 (3 × CH3), 40.0 (CH2), 45.8 (CH2), 77. 9 (C), 99.5 (C), 106.9 (CH, JC6-F = 25.8 Hz), 110.2 (CH, JC4-F = 26.0 Hz), 111.6 (CH, JC7-F = 10.1 Hz), 115.3 (C, JC7a-F = 4.5 Hz), 126.9 (C, JC3a-F = 11.2 Hz), 132.9 (CH), 133.6 (C), 155.6 (CO), 158.1 (C, JC5-F = 233 Hz), 192.6 (CS). Anal. Calcd. for: C16H20FN3O2S: C, 56.95; H, 5.97; N, 12.45. Found: C, 56.69; H, 6.25; N, 12.21.

3.1.5. General Procedure for the Synthesis of Thiazoles (1a–h)

A suspension of the proper thioamides 6a–d (2 mmol) and bromoacetyl derivatives 7a,b (2 mmol) in anhydrous ethanol (8 mL) was refluxed for 30 min. After cooling, the precipitate obtained, was filtered off, dried, and recrystallized from ethanol to give the desired thiazoles 1a–h.
Tert-Butyl (2-{3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethyl)carbamate (1a)
Orange solid; yield: 70%; mp: 229–230 °C; IR cm−1: 3348 (NH), 3090 (NH), 1684 (CO); 1H NMR (200 MHz, DMSO-d6) δ: 1.32 (s, 9H, 3 × CH3), 3.35–3.46 (m, 2H, CH2), 4.35 (t, 2H, J = 5.1 Hz, CH2), 7.06 (t, 1H, J = 5.0 Hz, NH), 7.28–7.33 (m, 2H, H-5′ and H-6′), 7.41 (dd, 1H, J = 7.9, 5.1 Hz, H-5′′), 7.59–7.64 (m. 1H, H-7′), 7.82 (s, 1H, H-5), 8.19 (s, 1H, H-2′), 8.23 (d, 1H, J = 2.2 Hz, H-2′′), 8.29-8.34 (m, 1H, H-4′), 8.43 (d, 1H, J = 5.1 Hz, H-6′′), 8.89 (d, 1H, J = 7.9 Hz, H-4′′), 12.40 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 28.1 (3 × CH3), 40.2 (CH2), 45.3 (CH2), 77.8 (C), 108.5 (CH), 109.7 (C), 110.6 (CH), 111.2 (C), 116.2 (CH), 120.3 (CH), 120.6 (C), 121.1 (CH), 122.4 (CH), 124.6 (C), 126.5 (CH), 129.9 (CH), 134.3 (CH), 136.8 (C), 137.7 (CH), 142.7 (C), 148.1 (C), 155.6 (C), 162.2 (CO). Anal. Calcd. for: C25H25N5O2S: C, 65.34; H, 5.48; N, 15.24. Found: C, 65.30; H, 5.62; N, 15.45.
Tert-Butyl (2-{3-[4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethyl)carbamate (1b)
Yellow solid; yield: 68%; mp: 187 °C; IR cm−1: 3335 (NH), 1705 (CO); 1H NMR (200 MHz, DMSO-d6) δ: 1.32 (s, 9H, 3 × CH3), 3.36–3.43 (m, 2H, CH2), 3.94 (s, 1H, CH3), 4.35 (t, 2H, J = 5.0 Hz, CH2), 7.05 (t, 1H, J = 4.6 Hz, NH), 7.27–7.32 (m, 3H, H-5′, H-6′ and H-5′′), 7.59–7.63 (m. 1H, H-7′), 7.73 (s, 1H, H-5), 8.15 (s, 1H, Ar), 8.22 (s, 1H, Ar), 8.33–8.41 (m, 2H, H-4′ and H-6′′), 8.67 (dd, 1H, J = 8.0, 1.4 Hz, H-4′′); 13C NMR (50, DMSO-d6) δ: 28.1 (3 × CH3), 31.8 (CH3), 40.2 (CH2), 45.2 (CH2), 77.8 (C), 107.6 (CH), 109.5 (C), 109.7 (C), 110.6 (CH), 116.1 (CH), 118.9 (C), 120.5 (CH), 121.0 (CH), 122.4 (CH), 124.6 (C), 129.7 (CH), 129.9 (CH), 131.3 (CH), 136.7 (C), 140.3 (CH), 145.0 (C), 148.4 (C), 155.6 (C), 162.1 (CO). Anal. Calcd. for: C26H27N5O2S: C, 65.94; H, 5.75; N, 14.79. Found: C, 65.80; H, 5.71; N, 14.97.
Tert-Butyl (2-{5-methoxy-3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethyl)carbamate (1c)
Yellow solid; yield: 87%; mp: 201 °C; IR cm−1: 3584 (NH), 3342 (NH), 1683 (CO); 1H NMR (200 MHz, DMSO-d6) δ: 1.32 (s, 9H, 3 × CH3), 3.34–3.39 (m, 2H, CH2), 3.90 (s, 3H, CH3), 4.31 (t, 2H, J = 5.7 Hz, CH2), 6.94 (dd, 1H, J = 8.9, 2.4 Hz, H-6′), 7.04 (t, 1H, J = 5.2 Hz, NH), 7.40 (dd, 1H, J = 7.9, 5.1 Hz, H-5′′), 7.52 (d, 1H, J = 8.9 Hz, H-7′), 7.79 (s, 1H, H-5), 7.89 (d, 1H, J = 2.3 Hz, H-2′′), 8.11 (s, 1H, H-2′), 8.22 (d, 1H, J = 2.4 Hz, H-4′), 8.45 (d, 1H, J = 5.1 Hz, H-6′′), 8.l9 (d, 1H, J = 7.9 Hz, H-4′′), 12.43 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 28.1 (3 × CH3), 40.2 (CH2), 45.4 (CH2), 55.2 (CH3), 77.8 (C), 102.0 (CH), 107.9 (CH), 109.4 (C), 111.1 (C), 111.5 (CH), 112.5 (CH), 116.0 (CH), 120.4 (C), 125.2 (C), 126.2 (CH), 130.1 (CH), 131.8 (C), 133.9 (CH), 138.2 (CH), 143.0 (C), 148.3 (C), 154.9 (C), 155.6 (C), 161.5 (CO). Anal. Calcd. for: C26H27N5O3S: C, 63.78; H, 5.56; N, 14.30. Found: C, 63.52; H, 5.50; N, 14.41.
Tert-Butyl (2-{5-methoxy-3-[4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethyl)carbamate (1d)
Yellow solid; yield: 61%; mp: 191 °C; IR cm−1: 3360 (NH), 1707 (CO); 1H NMR (200 MHz, DMSO-d6) δ: 1.33 (s, 9H, 3 × CH3), 3.31–3.40 (m, 2H, CH2), 3.91 (s, 1H, CH3), 3.94 (s, 1H, CH3), 4.30 (t, 2H, J = 4.7 Hz, CH2), 6.95 (dd, 1H, J = 8.9, 2.4 Hz, H-6′), 7.04 (t, 1H, J = 5.5 Hz, NH), 7.28 (dd, 1H, J = 7.9, 4.7 Hz, H-5′′), 7.51 (d, 1H, J = 8.9 Hz, H-7′), 7.69 (s, 1H, H-5), 7.89 (d, 1H, J = 2.4 Hz, H-4′), 8.09 (s, 1H, Ar), 8.17 (s, 1H, Ar), 8.40 (dd, 1H, J = 4.7, 1.4 Hz, H-6′′), 8.77 (dd, 1H, J = 7.9, 1.4 Hz, H-4′′), 13C NMR (50 MHz, DMSO-d6) δ: 28.1 (3 × CH3), 31.2 (CH3), 40.2 (CH2), 45.5 (CH2), 55.1 (CH3), 77.8 (C), 101.5 (H), 106.7 (CH), 109.1 (C), 109.6 (C), 111.7 (CH), 112. 9 (CH), 116.0 (CH), 116.2 (CH), 118.9 (C), 124.9 (C), 129.2 (CH), 130.5 (CH), 131.8 (C), 143.0 (CH), 146.6 (C), 147.3 (C), 155.1 (C), 155.7 (C), 162.6 (CO). Anal. Calcd. for: C27H29N5O3S: C, 64.39; H, 5.80; N, 13.91. Found: C, 64.62; H, 5.65; N, 13.73.
Tert-Butyl (2-{5-bromo-3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethyl)carbamate (1e)
Very unstable compound, used in the next step without purification.
Tert-Butyl (2-{5-bromo-3-[4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethyl)carbamate (1f)
Orange solid; yield: 72%; mp: 203–204 °C; IR cm−1: 3337 (NH), 1704 (CO); 1H NMR (200 MHz, DMSO-d6) δ: 1.29 (s, 9H, 3 × CH3), 3.35–3.39 (m, 2H, CH2), 3.95 (s, 3H, CH3), 4.34 (t, 2H, J = 4.8 Hz, CH2), 6.99 (t, 1H, J = 5.7 Hz, NH), 7.30 (dd, 1H, J = 7.9, 4.7 Hz, H-5′′), 7.44 (dd, 1H, J = 8.8, 1.8 Hz, H-6′), 7.61 (d, 1H, J = 8.8 Hz, H-7′), 7.74 (s, 1H, H-5), 8.18 (s, 1H, Ar), 8.20 (s, 1H, Ar), 8.41 (dd, 1H, J = 4.7, 1.3 Hz, H-6′′), 8.51 (d, 1H, J = 1.8 Hz, H-4′), 8.69 (dd, 1H, J = 7.9, 1.7 Hz, H-4′′); 13C NMR (50 MHz, DMSO-d6) δ: 28.0 (3 × CH3), 31.5 (CH3), 40.2 (CH2), 45.6 (CH2), 77.8 (C), 99.5 (C), 107.6 (CH), 109.2 (C), 109.4 (C), 112.8 (CH), 113.6 (C), 116.1 (CH), 118.4 (C), 122.7 (CH), 124.9 (CH), 126.3 (C), 129.1 (CH), 130.5 (CH), 131.2 (CH), 135.6 (C), 141.2 (CH), 149.0 (C), 155.6 (C), 161.4 (CO). Anal. Calcd. for: C26H26BrN5O2S: C, 56.52; H, 4.74; N, 12.68. Found: C, 56.66; H, 4.92; N, 12.60.
Tert-Butyl (2-{5-fluoro-3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethyl)carbamate (1g)
Very unstable compound, used in the next step without purification
Tert-Butyl (2-{5-fluoro-3-[4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethyl)carbamate (1h)
Yellow solid; yield: 86%; mp: 193–194 °C; IR cm−1: 3329 (NH), 1704 (CO); 1H NMR (200 MHz, DMSO-d6) δ:. 1.30 (s, 9H, 3 × CH3), 3.35–3.41 (m, 2H, CH2), 3.96 (s, 3H, CH3), 4.34 (t, 2H, J = 4.9 Hz, CH2), 7.04 (t, 1H, J = 5.1 Hz, NH), 7.18 (td, 1H, J = 11.7, 9.1, 2.5 Hz, H-6′), 7.32 (dd, 1H, J = 7.9, 4.8 Hz, H-5′′), 7.74 (s, 1H, H-5), 7.64 (dd, 1H, J = 9.1, 4.6 Hz, H-7′), 8.09 (dd, 1H, J = 11.7, 2.5 Hz, H-4′), 8.22 (s, 1H, Ar), 8.25 (s, 1H, Ar), 8.42 (dd, 1H, J = 4.8, 2.0 Hz, H-6′′), 8.68 (dd, 1H, J = 7.9, 2.0 Hz, H-4′′); 13C NMR (50 MHz, DMSO-d6) δ: 28.1 (3 × CH3), 31.9 (CH3), 40.2 (CH2), 45.6 (CH2), 99.5 (CH), 105.5 (CH, JC6′-F = 25.0 Hz), 107.8 (CH), 109.4 (C), 109.8 (C), 110.0 (C), 110.7 (CH, JC4′-F = 26.6 Hz), 111.9 (CH, JC7-F = 9.7 Hz), 112.0 (C), 116.1 (CH), 118.5 (C), 124.9 (C, JC3′a-F = 10.2 Hz), 129.9 (CH), 131.6 (CH), 133.5 (C), 140.0 (CH), 148.7 (C), 155.8 (C), 158.0 (CH, JC5-F = 246 Hz), 161.7 (CO). Anal. Calcd. for: C26H26FN5O2S: C, 63.53; H, 5.33; N, 14.25. Found: C, 63.67; H, 5.29; N, 14.32.

3.1.6. General Procedure for the Synthesis of Thiazoles (1i–p)

To a suspension of appropriate thiazoles 1a–h (0.38 mmol) in DCM (5 mL) trifluoroacetic acid (0.54 mL, 7.0 mmol) was added and the mixture was heated under reflux for 24 h. After cooling, the mixture was neutralized with saturated aqueous sodium hydrogen carbonate solution and extracted with dichloromethane (3 × 20 mL). The organic phases were dried (anhydrous Na2SO4), evaporated under reduced pressure, and the residue was recrystallized with ethanol to afford the desired thiazoles 7i–p.
2-{3-[4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethanamine (1i)
Yellow solid; yield: 65%; mp: 165 °C; IR cm−1: 3608, 3558 (NH2), 3249 (NH); 1H NMR (200 MHz, DMSO-d6) δ: 3.34–3.37 (m, 2H, CH2), 4.56 (t, 2H, J = 5.7 Hz, CH2), 7.29–7.37 (m, 3H, H-5′, H-6′ and H-5′′), 7.69-7.73 (m. 1H, H-7′), 7.80 (s, 1H, H-5), 8.02 (bs, 2H, NH2), 8.17 (d, 1H, J = 2.4 Hz, H-2′′), 8.28 (s, 1H, H-2′), 8.28–8.39 (m, 2H, H-4′ and H-6′′), 8.76 (d, 1H, J = 7.7 Hz, H-4′′), 12.22 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 38.5 (CH2), 43.5 (CH2), 107.8 (C), 110.5 (CH), 110.6 (CH), 116. 2 (CH), 118.7 (C), 120.6 (CH), 121.4 (CH), 122.7 (CH), 124.9 (C), 125.5 (CH), 129.8 (CH), 131.1 (CH), 131.3 (C), 136.5 (C), 140.7 (CH), 146.0 (C), 149.2 (C), 161.6 (CO). Anal. Calcd. for: C20H17N5S: C, 66.83; H, 4.77; N, 19.48. Found: C, 66.97; H, 4.63; N, 19.65.
2-{3-[4-(1-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethanamine (1j)
Yellow solid; yield: 70%; mp: 179 °C; IR cm−1: 3598, 3559 (NH2); 1H NMR (200 MHz, DMSO-d6) δ: 3.30–3.40 (m, 2H, CH2), 3.94 (s, 1H, CH3), 4.56 (t, 2H, J = 5.9 Hz, CH2), 7.26-7.40 (m, 3H, H-5′, H-6′ and H-5′′), 7.69-7.75 (m. 2H, H-5 and H-7′), 8.03 (bs, 2H, NH2), 8.22 (s, 1H, Ar), 8.27 (s, 1H, Ar), 8.38–8.43 (m, 2H, H-4′ and H-6′′), 8.67 (dd, 1H, J = 7.9, 1.4 Hz, H-4′′); 13C NMR (50 MHz, DMSO-d6) δ: 31.1 (CH3), 38.5 (CH2), 43.5 (CH2), 107.1 (CH), 109.0 (C), 110.6 (CH), 116.2 (CH), 117.6 (C), 120.8 (CH), 121.3 (CH), 122.7 (CH), 125.0 (C), 128.9 (CH), 129.2 (CH), 129.8 (CH), 136.5 (C), 142.4 (CH), 147.2 (C), 149.3 (C), 158.7 (C), 161.6 (CO). Anal. Calcd. for: C21H19N5S: C, 67.53; H, 5.13; N, 18.75. Found: C, 67.48; H, 5.10; N, 18.99.
2-{5-Methoxy-3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethanamine (1k)
Yellow solid; yield: 70%; mp: 220 °C; IR cm−1: 3609, 3557 (NH2), 3452 (NH); 1H NMR (200 MHz, DMSO-d6) δ: 3.29–3.37 (m, 2H, CH2), 3.91 (s, 1H, CH3), 4.52 (t, 2H, J = 5.7 Hz, CH2),7.00 (dd, 1H, J = 8.9, 2.4 Hz, H-6′), 7.30 (dd, 1H, J = 7.9, 4.9 Hz, H-5′′), 7.62 (d, 1H, J = 8.9 Hz, H-7′), 7.77 (s, 1H, H-5), 7.94 (d, 1H, J = 2.3 Hz, H-2′′), 8.03 (bs, 2H, NH2), 8.17 (d, 1H, J = 2.4 Hz, H-4′), 8.21 (s, 1H, H-2′), 8.38 (d, 1H, J = 4.9 Hz, H-6′′), 8.86 (d, 1H, J = 7.9 Hz, H-4′′), 12.23 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 38.5 (CH2), 43.6 (CH2), 55.2 (CH3), 102.2 (CH), 107.2 (CH), 110.3 (C), 110.5 (C), 111.5 (CH), 112.7 (CH), 116.0 (CH), 118.6 (C), 125.2 (CH), 125.5 (C), 130.1 (CH), 130.9 (CH), 131.5 (C), 141.0 (CH), 146.3 (C), 149.3 (C), 155.1 (C), 161.9 (C). Anal. Calcd. for: C21H19N5OS: C, 64.76; H, 4.92; N, 17.98. Found: C, 64.92; H, 4.83; N, 18.09.
2-{5-Methoxy-3-[4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethanamine (1l)
Yellow solid; yield: 75%; mp: 232 °C; IR cm−1: 3608, 3558 (NH2); 1H NMR (200 MHz, DMSO-d6) δ: 3.27-3.39 (m, 2H, CH2), 3.92 (s, 3H, CH3), 3.93 (s, 3H, CH3), 4.51 (t, 2H, J = 6.1 Hz, CH2), 7.00 (dd, 1H, J = 8.9, 2.5 Hz, H-6′), 7.26 (dd, 1H, J = 7.9, 4.7 Hz, H-5′′), 7.61 (d, 1H, J = 8.9 Hz, H-7′), 7.71 (s, 1H, H-5), 7.94 (d, 1H, J = 2.5 Hz, H-4′), 7.99 (bs, 1H, NH2), 8.17 (s, 1H, Ar), 8.19 (s, 1H, Ar), 8.39 (dd, 1H, J = 4.7, 1.4 Hz, H-6′′), 8.75 (dd, 1H, J = 7.9, 1.4 Hz, H-4′′), 13C NMR (50 MHz, DMSO-d6) δ: 31.2 (CH3), 38.6 (CH32), 43.6 (CH2), 55.3 (CH3), 102.4 (CH), 106.8 (CH), 109.1 (C), 110.3 (C), 111.4 (CH), 112.6 (CH), 116.0 (CH), 117.9 (C), 125.5 (C), 128.6 (CH), 129.6 (CH), 130.1 (CH), 131.5 (C), 142.3 (CH), 146.8 (C), 155.1 (C), 158.8 (C), 161.9 (C). Anal. Calcd. for: C22H21N5OS: C, 65.49; H, 5.25; N, 17.36. Found: C, 65.77; H, 5.17; N, 17.50.
2-{5-Bromo-3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethanamine (1m)
Orange solid; yield: 85%; mp: 180 °C; IR cm−1: 3609, 3558 (NH2), 3408 (NH); 1H NMR (200 MHz, DMSO-d6) δ: 3.29-3.40 (m, 2H, CH2), 4.55 (t, 2H, J = 5.6 Hz, CH2), 7.32 (dd, 1H, J = 7.9, 4.9 Hz, H-5′′), 7.51 (dd, 1H, J = 8.7, 1.8 Hz, H-6′), 7.72 (d, 1H, J = 8.7 Hz, H-7′), 7.82 (s, 1H, H-5), 7.99 (bs, 1H, NH2), 8.15 (d, 1H, J = 2.4 Hz, H-2′′), 8.33 (s, 1H, H-2′), 8.39 (dd, 1H, J = 4.9 ,1.7, H-6′′), 8.57 (d, 1H, J = 1.8 Hz, H-4′), 8.76 (dd, 1H, J = 7.9, 1.7 Hz, H-4′′), 12.22 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 38.5 (CH2), 43.7 (CH2), 108.2 (CH), 110.0 (C), 110.5 (C), 112.9 (CH), 114.0 (C), 116.1 (CH), 119.0 (C), 122.9 (CH), 125.2 (CH), 125.6 (CH), 126.6 (C), 131.2 (CH), 131.5 (CH), 135.4 (C), 140.4 (CH), 145.5 (C), 149.2 (C), 161.2 (C). Anal. Calcd. for: C20H16BrN5S: C, 54.80; H, 3.68; N, 15.98. Found: C, 54.91; H, 3.64; N, 16.10.
2-{5-Bromo-3-[4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethanamine (1n)
Yellow solid; yield: 60%; mp: 166 °C; IR cm−1: 3609, 3558 (NH2); 1H NMR (200 MHz, DMSO-d6) δ: 3.72–3.82 (m, 2H, CH2), 4.37 (s, 3H, CH3), 4.97 (t, 2H, J = 5.7 Hz, CH2), 7.70 (dd, 1H, J = 7.9, 4.7 Hz, H-5′′), 7.93 (dd, 1H, J = 8.8, 1.9 Hz, H-6′), 8.14 (d, 1H, J = 8.8 Hz, H-7′), 8.18 (s, 1H, H-5), 8.43 (bs, 2H, NH2), 8.59 (s, 1H, Ar), 8.74 (s, 1H, Ar), 8.82 (dd, 1H, J = 4.7, 1.4 Hz, H-6′′), 8.98 (d, 1H, J = 1.9 Hz, H-4′), 8.69 (dd, 1H, J = 7.9, 1.7 Hz, H-4′′); 13C NMR (50 MHz, DMSO-d6) δ: 31.1 (CH3), 38.5 (CH2), 43.7 (CH2), 107.4 (CH), 108.8 (C), 110.1 (C), 112.8 (CH), 114.0 (C), 116.1 (CH), 117.6 (C), 122.9 (CH), 125.2 (CH), 126.6 (C), 128.7 (CH), 129.0 (CH), 131.1 (CH), 135.4 (C), 142.6 (CH), 147.5 (C), 157.9 (C), 161.1 (C). Anal. Calcd. for: C21H18BrN5S: C, 55.76; H, 4.01; N, 15.48. Found: C, 55.50; H, 3.99; N, 15.45.
2-{5-Fluoro-3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethanamine (1o)
Brown solid; yield: 91%; mp: 203–204 °C; IR cm−1: 3609, 3557 (NH2), 3379 (NH); 1H NMR (200 MHz, DMSO-d6) δ: 3.31–3.40 (m, 2H, CH2), 4.57 (t, 2H, J = 5.7 Hz, CH2), 7.19–7.37 (m, 2H, H-5′′ and H-6′), 7.76 (dd, 1H, J = 9.0, 4.4 Hz, H-7′), 7.82 (s, 1H, H-5), 8.02-8.11 (m, 3H, H-4′ and NH2), 8.20 (d, 1H, J = 2.3 Hz, H-2′′), 8.36–8.40 (m, 2H, H-2′ and H-6′′), 8.76 (d, 1H, J = 7.4 Hz, H-4′′), 12.26 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 38.5 (CH2), 43.7 (CH2), 105.5 (CH, JC6′-F = 23.7 Hz), 107.9 (CH), 110.5 (C), 110.9 (CH, JC4′-F = 25.3 Hz), 112.0 (C), 112.2 (CH), 116.1 (CH), 118.6 (C), 125.2 (C, JC3a′-F = 10.8 Hz), 125.4 (CH), 130.9 (CH), 131.5 (CH), 133.3 (C), 140.7 (CH), 146.0 (C), 149.2 (C), 158.3 (C, JC5-F = 235 Hz), 161.4 (C). Anal. Calcd. for: C20H16FN5S: C, 63.64; H, 4.27; N, 18.55. Found: C, 63.75; H, 4.23; N, 18.52.
2-{5-Fluoro-3-[4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indol-1-yl}ethanamine (1p)
Yellow solid; yield: 70%; mp: 238–239 °C; IR cm−1: 3609, 3557 (NH2); 1H NMR (200 MHz, DMSO-d6) δ: 3.73–3.83 (m, 2H, CH2), 4.37 (s, 3H, CH3), 4.97 (t, 2H, J = 5.8 Hz, CH2), 7.62–7.74 (m, 2H, H-5′′ and H-6′), 8.13–8.19 (m, 3H, NH2 and H-7′), 8.39 (s, 1H, Ar), 8.55 (dd, 1H, J = 11.6, 2.5 Hz, H-4′), 8.65 (s, 1H, Ar), 8.74 (s, 1H, Ar), 8.81 (dd, 1H, J = 4.7, 1.4 Hz, H-6′′), 9.05 (dd, 1H, J = 8.0, 1.4 Hz, H-4′′). 13C NMR (50 MHz, DMSO-d6) δ: 31.2 (CH3), 38.5 (CH2), 43.7 (CH2), 105.7 (CH, JC6′-F = 23.7 Hz), 107.2 (CH), 111.0 (CH, JC4′-F = 25.9 Hz), 112.0 (CH, JC7′-F = 10.0 Hz), 112.3 (C), 116.2 (CH), 117.6 (C), 125.3 (C, JC3a′-F = 10.9 Hz), 129.0 (CH), 129.1 (CH), 131.5 (CH), 133.3 (C), 142.3 (CH), 147.0 (C), 149.3 (C), 158.0 (C), 158.6 (C, JC5-F = 265 Hz), 158.7 (C). Anal. Calcd. for: C21H18FN5S: C, 64.43; H, 4.63; N, 17.89. Found: C, 64.57; H, 4.57; N, 18.08.

3.2. Biology

3.2.1. MICs Determination

MICs of the thiazole derivatives 1a–p and 2a–u towards free living form (planktonic) of three reference strains of S. aureus ATCC 25923 and 6538 and P. aeruginosa ATCC 15442, were determined by using a microdilution method as recommended by CLSI for bacteria that grow aerobically (CLSI) [43] and Tryptic Soy Broth (VWR International, Leuven, Belgium) as medium [44].

3.2.2. Inhibition of Biofilm Formation (Crystal Violet Method).

Bacterial strains were incubated in test tubes with Tryptic Soy Broth (TSB) (5 mL) containing 2% w/v glucose at 37 °C for 24 h. Afterwards, the bacterial suspensions were diluted to achieve a turbidity equivalent to a 0.5 McFarland standard. The diluted suspension (2.5 μL) was added to each well of a single cell culture polystyrene sterile, flat-bottom 96-well plate filled with TSB (100 μL) with 2% w/v glucose. Sub-MIC concentration values of all compounds were directly added to the wells to reach concentrations ranging from 100 to 0.1 μg/mL to assess IC50 values that are the concentrations at which the percentage of inhibition of biofilm formation (see below) is equal to 50%, we calculated this value by using a linear regression graph in Excel. Plates were incubated at 37 °C for 24 h. After biofilm growth, the content of each well was removed, wells were washed twice with sterile Phosphate-buffered saline (PBS) 1× and stained with 150 μL of 0.1% w/v crystal violet solution for 30 min. at room temperature. Excess solution was removed, and the plate was washed twice, by tap water. 33% v/v of acetic acid (125 μL) was added for 15 min to each stained well to solubilize the dye. Optical density (OD) was read at 540 nm using a microplate reader (Glomax Multidetection System Promega, Madison, Wisconsin, USA). The experiments were run at least in triplicates and three independent experiments were performed. [44]
The percentage of inhibition was calculated using the formula:
% of inhibition = [(OD growth control − OD sample)/OD growth control] × 100

3.2.3. Antibiofilm Activity (Crystal Violet Method)

A suspension of bacteria (0.5 McFarland standard) was obtained using the procedure described above for the inhibition of biofilm formation test. 2.5 μL of suspension was added to each well of a 96-wheel plate containing TSB (100 μL) with 2% w/v glucose. After the growth of a biofilm (24 h old), the content of each well was removed, wells were washed up twice with sterile PBS and then filled with fresh TSB medium (200 μL). After that, a screening concentration of 100 μg/mL of the thiazole derivatives were added. The microtiter plate was sealed and incubated at 37 °C for further 24 h. The content of each well was removed, wells were washed up twice with sterile PBS (100 μL to each well) and the 96-wheel plate was placed at 60 °C for 1 h before staining with a 0.1% w/v crystal violet solution. After 30 min, plates were washed with tap water to remove an excess of stain. Biofilm formation was determined by solubilizing crystal violet staining in 33% v/v acetic acid (125 μL) for 15 min and measuring the absorbance at 540 nm using a microplate reader (Glomax Multidetection System Promega). To calculate the percentages of inhibition the formula above reported was used.

3.2.4. Screening as Sortase A (SrtA) Inhibitors

The compounds 1a and 1r, selected for their good activity in inhibiting biofilm formation of S.aureus, were screened at a single dose of 100 µM (1% DMSO) in black 96-well plates (Greiner Bio-One, Kremsmunster, Austria). A known sortase inhibitor, 4-(hydroxymercuri)benzoic acid, was used as positive control. The inhibitory activity of the three compounds was assessed by quantifying the increase in fluorescence intensity upon cleavage of the fluorescence resonance energy transfer (FRET) substrate into two separate fragments resulting in the release of 5-Fam fluorescence, which can be monitored at excitation/emission = 490/520 nm. A commercial kit (SensoLyte® 520 Sortase A Activity Assay Kit Fluorimetric, Cambridge Bioscience, Cambridge, UK) was used with slight modifications. Briefly, the reactions were performed in a volume of 100 µL containing 1× assay buffer, 2.5 µg/mL SrtA protease recombinant, 4 µM fluorescent peptide substrate, and the prescribed concentrations of the test compounds or the positive control. The peptide substrate without the recombinant SrtA was incubated in the same manner and used as a negative control. The reactions were conducted adding tested compounds and diluted enzyme solution to the microplate wells. Simultaneously setup the following control wells. Then sortase substrate solutions were added into each well. For kinetic reading, fluorescence at Ex/Em = 490/520 nm was continuously recorded every 5 min for 60 min. All fluorescence measurements are expressed in relative fluorescence units (RFU).

4. Conclusions

Marine-derived compounds and their synthetic analogues that prevent the formation of biofilms without interfering with microbial viability could be advantageous when developing a new generation of anti-virulence agents counteracting antibiotic resistance.
New thiazole nortopsentin analogues were conveniently synthesized and tested as inhibitors of biofilm formation against Gram-positive and Gram-negative bacteria. Compounds 1a–p and 2a–u showed a good activity in inhibiting biofilm formation, in particular against Gram-positive bacteria. The inhibition of SrtA as a mechanism of action was investigated but results suggested that SrtA was not found to be involved in the inhibition of the biofilm formation of these compounds.
Compounds 1a and 1r could be considered interesting lead compounds for the development of a new class of anti-biofilm agents useful in counteracting the phenomenon of the antibiotic resistance.

Author Contributions

Anna Carbone, Stella Cascioferro, Barbara Parrino, Virginia Spanò, and Alessandra Montalbano performed chemical research and analyzed data. Maria Grazia Cusimano and Domenico Schillaci performed biological research and analyzed data. Girolamo Cirrincione, Patrizia Diana, Paola Barraja, and Domenico Schillaci participated in the design of the research and the writing of the manuscript. All authors read and approved the final manuscript.

Funding

This research received no external funding.

Acknowledgments

This work was financially supported by Ministero dell’Istruzione dell’Università e della Ricerca (MIUR).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Blair, J.M.A.; Webber, M.A.; Baylay, A.J.; Ogbolu, D.O.; Piddock, L.J.V. Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol. 2015, 13, 42–51. [Google Scholar] [CrossRef] [PubMed]
  2. Schillaci, D.; Spanò, V.; Parrino, B.; Carbone, A.; Montalbano, A.; Barraja, P.; Diana, P.; Cirrincione, G.; Cascioferro, S. Pharmaceutical approaches to target antibiotic resistance mechanisms. J. Med. Chem. 2017, 80, 8268–8297. [Google Scholar] [CrossRef] [PubMed]
  3. RömLing, U.; Balsalobre, C. Biofilm infections, their resilience to therapy and innovative treatment strategies. J. Intern. Med. 2012, 272, 541–561. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Costerton, J.W.; Stewart, P.S.; Greenberg, E.P. Bacterial biofilms: A common cause of persistent infections. Science 1999, 284, 1318–1322. [Google Scholar] [CrossRef] [PubMed]
  5. Roy, R.; Tiwari, M.; Donelli, G.; Tiwari, V. Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action. Virulence 2018, 9, 522–554. [Google Scholar] [CrossRef] [PubMed]
  6. Schillaci, D.; Spinello, A.; Cusimano, M.G.; Cascioferro, S.; Barone, G.; Vitale, M.; Arizza, V. A peptide from human β thymosin as a platform for the development of new anti-biofilm agents for Staphylococcus spp. and Pseudomonas aeruginosa. World J. Microbiol. Biotechnol. 2016, 32, 124. [Google Scholar] [CrossRef] [PubMed]
  7. Cascioferro, S.; Maggio, B.; Raffa, D.; Raimondi, M.V.; Cusimano, M.G.; Schillaci, D.; Manachini, B.; Leonchiks, A.; Daidone, G. A new class of phenylhydrazinylidene derivatives as inhibitors of Staphylococcus aureus biofilm formation. Med. Chem. Res. 2016, 25, 870–878. [Google Scholar] [CrossRef]
  8. Cascioferro, S.; Maggio, B.; Raffa, D.; Raimondi, M.V.; Cusimano, M.G.; Schillaci, D.; Manachini, B.; Plescia, F.; Daidone, G. Synthesis and biofilm formation reduction of pyrazole-4-carboxamide derivatives in some Staphylococcus aureus strains. Eur. J. Med. Chem. 2016, 123, 58–68. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Koo, H.; Allan, R.N.; Howlin, R.P.; Stoodley, P.; Hall-Stoodley, L. Targeting microbial biofilms: Current and prospective therapeutic strategies. Nat. Rev. Microbiol. 2017, 15, 740–755. [Google Scholar] [CrossRef] [PubMed]
  10. Rane, R.A.; Karpoormath, R.; Naphade, S.S.; Bangalore, P.; Shaikh, M.; Hampannavar, G. Novel synthetic organic compounds inspired from antifeedant marine alkaloids as potent bacterial biofilm inhibitors. Bioorg. Chem. 2015, 61, 66–73. [Google Scholar] [CrossRef] [PubMed]
  11. Hodnik, Z.; Los, J.M.; Zula, A.; Zidar, N.; Jakopin, Z.; Los, M.; Dolenc, M.S.; Ilas, J.; Wegrzyn, G.; Masic, L.P.; et al. Inhibition of biofilm formation by conformationally constrained indole-based analogues of the marine oroidin. Bioorg. Med. Chem. Lett. 2014, 24, 2530–2534. [Google Scholar] [CrossRef] [PubMed]
  12. Jang, K.H.; Chung, S.-C.; Shin, J.; Lee, S.-H.; Kim, T.-I.; Lee, H.-S.; Oh, K.-B. Aaptamines as sortase A inhibitors from the tropical sponge Aaptos aaptos. Bioorg. Med. Chem. Lett. 2005, 15, 4927–4931. [Google Scholar] [CrossRef] [PubMed]
  13. Cascioferro, S.; Totsika, M.; Schillaci, D. Sortase A: An Ideal Target for Anti-Virulence Drug Development. Microb. Pathog. 2014, 77C, 105–112. [Google Scholar] [CrossRef] [PubMed]
  14. Cascioferro, S.; Raffa, D.; Maggio, B.; Raimondi, M.V.; Schillaci, D.; Daidone, G. Sortase A Inhibitors: Recent Advances and Future Perspectives. J. Med. Chem. 2015, 58, 9108–9123. [Google Scholar] [CrossRef] [PubMed]
  15. Oh, K.-B.; Mar, W.; Kim, S.; Kim, J.-Y.; Oh, M.-N.; Kim, J.-G.; Shin, D.; Sim, C.J.; Shin, J. Bis(indole)alkaloids as sortase A inhibitors from the sponge Spongosorites sp. Bioorg. Med. Chem. Lett. 2005, 15, 4927–4931. [Google Scholar] [CrossRef] [PubMed]
  16. Montalbano, A.; Parrino, B.; Diana, P.; Barraja, P.; Carbone, A.; Spanò, V.; Cirrincione, G. Synthesis of the new oligopeptide pyrrole derivative isonetropsin and its one pyrrole unit analogue. Tetrahedron 2013, 69, 2550–2554. [Google Scholar] [CrossRef]
  17. Barraja, P.; Caracausi, L.; Diana, P.; Spanò, V.; Montalbano, A.; Carbone, A.; Parrino, B.; Cirrincione, G. Synthesis and Antiproliferative Activity of the Ring System [1,2]Oxazolo[4,5-g]indole. ChemMedChem 2012, 7, 1901–1904. [Google Scholar] [CrossRef] [PubMed]
  18. Parrino, B.; Ullo, S.; Attanzio, A.; Spanò, V.; Cascioferro, S.; Montalbano, A.; Barraja, P.; Tesoriere, L.; Diana, P.; Cirrincione, G. New tripentone analogs with antiproliferative activity. Molecules 2017, 22, 1–13. [Google Scholar]
  19. Diana, P.; Stagno, A.; Barraja, P.; Montalbano, A.; Carbone, A.; Parrino, B.; Cirrincione, G. Synthesis of the new ring system pyrrolizino[2,3-b]indol-4(5H)-one. Tetrahedron 2011, 67, 3374–3379. [Google Scholar] [CrossRef]
  20. Barraja, P.; Spanò, V.; Giallombardo, D.; Diana, P.; Montalbano, A.; Carbone, A.; Parrino, B.; Cirrincione, G. Synthesis of [1,2]oxazolo[5,4-e]indazoles as antitumour agents. Tetrahedron 2013, 69, 6474–6477. [Google Scholar] [CrossRef]
  21. Spanò, V.; Montalbano, A.; Carbone, A.; Parrino, B.; Diana, P.; Cirrincione, G.; Castagliuolo, I.; Brun, P.; Issinger, O.-G.; Tisi, S.; et al. Synthesis of a new class of pyrrolo[3,4-h]quinazolines with antimitotic activity. Eur. J. Med. Chem. 2014, 74, 340–357. [Google Scholar]
  22. Parrino, B.; Carbone, A.; Muscarella, M.; Spanò, V.; Montalbano, A.; Barraja, P.; Salvador, A.; Vedaldi, D.; Cirrincione, G.; Diana, P. 11H-Pyrido[3′,2′:4,5]pyrrolo[3,2-c]cinnoline and pyrido[3′,2′:4,5]pyrrolo[1,2-c][1,2,3]benzotriazine: Two new ring systems with antitumor activity. J. Med. Chem. 2014, 57, 9495–9511. [Google Scholar] [CrossRef] [PubMed]
  23. Parrino, B.; Carbone, A.; Ciancimino, C.; Spanò, V.; Montalbano, A.; Barraja, P.; Cirrincione, G.; Diana, P.; Sissi, C.; Palumbo, M.; et al. Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: In vitro antiproliferative activity and molecular mechanism(s) of action. Eur. J. Med. Chem. 2015, 94, 149–162. [Google Scholar] [CrossRef] [PubMed]
  24. Parrino, B.; Carbone, A.; Spanò, V.; Montalbano, A.; Giallombardo, D.; Barraja, P.; Attanzio, A.; Tesoriere, L.; Palumbo, M.; Sissi, C.; et al. Aza-isoindolo and isoindolo-azaquinoxaline derivatives with antiproliferative activity. Eur. J. Med. Chem. 2015, 94, 367–377. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Spanò, V.; Parrino, B.; Carbone, A.; Montalbano, A.; Salvador, A.; Brun, P.; Vedaldi, D.; Diana, P.; Cirrincione, G.; Barraja, P. Pyrazolo[3,4-h]quinolines promising photosensitizing agents in the treatment of cancer. Eur. J. Med. Chem. 2015, 102, 334–351. [Google Scholar] [CrossRef] [PubMed]
  26. Diana, P.; Stagno, A.; Barraja, P.; Carbone, A.; Parrino, B.; Dall’Acqua, F.; Vedaldi, D.; Salvador, A.; Brun, P.; Castagliuolo, I.; et al. Synthesis of triazeno-azaindoles a new class of triazenes with antitumor activity. ChemMedChem 2011, 6, 1291–1299. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Spanò, V.; Pennati, M.; Parrino, B.; Carbone, A.; Montalbano, A.; Cilibrasi, V.; Zuco, V.; Lopergolo, A.; Cominetti, D.; Diana, P.; et al. Preclinical activity of new [1,2]oxazolo[5,4-e]isoindole derivatives in diffuse malignant peritoneal mesothelioma. J. Med. Chem. 2016, 59, 7223–7238. [Google Scholar]
  28. Barraja, P.; Diana, P.; Spanò, V.; Montalbano, A.; Carbone, A.; Parrino, B.; Cirrincione, G. An efficient synthesis of pyrrolo[3′,2′:4,5]thiopyrano[3,2-b]pyridin-2-one: A new ring system of pharmaceutical interest. Tetrahedron 2012, 68, 5087–5094. [Google Scholar] [CrossRef]
  29. Spanò, V.; Frasson, I.; Giallombardo, D.; Doria, F.; Parrino, B.; Carbone, A.; Montalbano, A.; Nadai, M.; Diana, P.; Cirrincione, G.; et al. Synthesis and antiproliferative mechanism of action of pyrrole[3′,2′:6,7]cyclohepta[1,2-d]pyrimidin-2-amines as singlet oxygen photosensitizers. Eur. J. Med. Chem. 2016, 123, 447–461. [Google Scholar]
  30. Parrino, B.; Ciancimino, C.; Carbone, A.; Spanò, V.; Montalbano, A.; Barraja, P.; Cirrincione, G.; Diana, P. Synthesis of isoindolo[1,4]benzoxazinone and isoindolo[1,5]benzoxazepine: Two new ring systems of pharmaceutical interest. Tetrahedron 2015, 71, 7332–7338. [Google Scholar] [CrossRef]
  31. Spanò, V.; Pennati, M.; Parrino, B.; Carbone, A.; Montalbano, A.; Lopergolo, A.; Zuco, V.; Cominetti, D.; Diana, P.; Cirrincione, G.; et al. [1,2]oxazolo[5,4-e]isoindoles as promising tubulin polymerization inhibitors. Eur. J. Med. Chem. 2016, 124, 840–851. [Google Scholar]
  32. Spanò, V.; Montalbano, A.; Carbone, A.; Parrino, B.; Barraja, P.; Diana, P.; Cirrincione, G. Convenient synthesis of pyrrolo[3,4-g]indazole. Tetrahedron 2013, 69, 9839–9847. [Google Scholar] [CrossRef]
  33. Spanò, V.; Giallombardo, D.; Cilibrasi, V.; Parrino, B.; Carbone, A.; Montalbano, A.; Frasson, I.; Salvador, A.; Richter, S.N.; Doria, F.; et al. Pyrrolo[3’,2’:6,7]cyclohepta[1,2-b]pyridines with potent photo-antiproliferative activity. Eur. J. Med. Chem. 2017, 128, 300–318. [Google Scholar]
  34. Carbone, A.; Parrino, B.; Barraja, P.; Spanò, V.; Cirrincione, G.; Diana, P.; Maier, A.; Kelter, G.; Fiebig, H.-H. Synthesis and antiproliferative activity of 2,5-bis(3′-indolyl)pyrroles, analogues of the marine alkaloid Nortopsentin. Mar. Drugs 2013, 11, 643–654. [Google Scholar] [CrossRef] [PubMed]
  35. Carbone, A.; Pennati, M.; Barraja, P.; Montalbano, A.; Parrino, B.; Spanò, V.; Lopergolo, A.; Sbarra, S.; Doldi, V.; Zaffaroni, N.; et al. Synthesis and antiproliferative activity of substituted 3[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[3,2-b]piridine, marine alkaloid nortopsentin analogues. Curr. Med. Chem. 2014, 21, 1654–1666. [Google Scholar] [CrossRef] [PubMed]
  36. Carbone, A.; Parrino, B.; Di Vita, G.; Attanzio, A.; Spanò, V.; Montalbano, A.; Barraja, P.; Tesoriere, L.; Livrea, M.A.; Diana, P.; Cirrincione, G. Synthesis and antiproliferative activity of thiazolyl-bis-pyrrolo[2,3-b]pyridines and indolyl-thiazolyl-pyrrolo[2,3-c]pyridines, nortopsentin analogues. Mar. Drugs 2015, 13, 460–492. [Google Scholar] [CrossRef] [PubMed]
  37. Parrino, B.; Carbone, A.; Di Vita, G.; Ciancimino, C.; Attanzio, A.; Spanò, V.; Montalbano, A.; Barraja, P.; Tesoriere, L.; Livrea, M.A.; et al. 3-[4-(1H-Indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines, nortopsentin analogues with antiproliferative activity. Mar. Drugs 2015, 13, 1901–1924. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Spanò, V.; Attanzio, A.; Cascioferro, S.; Carbone, A.; Montalbano, A.; Barraja, P.; Tesoriere, L.; Cirrincione, G.; Diana, P.; Parrino, B. Synthesis and antitumor activity of new thiazole nortopsentin analogs. Mar. Drugs 2016, 14, 226–243. [Google Scholar] [CrossRef] [PubMed]
  39. Parrino, B.; Attanzio, A.; Spanò, V.; Cascioferro, S.; Montalbano, A.; Barraja, P.; Tesoriere, L.; Diana, P.; Cirrincione, G.; Carbone, A. Synthesis, antitumor activity and CDK1 inhibiton of new thiazole nortopsentin analogues. Eur. J. Med. Chem. 2017, 138, 371–383. [Google Scholar] [CrossRef] [PubMed]
  40. Carbone, A.; Pennati, M.; Parrino, B.; Lopergolo, A.; Barraja, P.; Montalbano, A.; Spanò, V.; Sbarra, S.; Doldi, V.; De Cesare, M.; et al. Novel 1H-pyrrolo[2,3-b]pyridine derivatives nortopsentin analogues: Synthesis and antitumor activity in peritoneal mesothelioma experimental models. J. Med. Chem. 2013, 56, 7060–7072. [Google Scholar] [CrossRef] [PubMed]
  41. Zhang, L.; Wen, Q.; Jin, J.; Wang, C.; Lu, P.; Wang, Y. Cyanation of indoles with benzyl cyanide as the cyanide anion surrogate. Tetrahedron 2013, 69, 4236–4240. [Google Scholar] [CrossRef]
  42. Luescher, M.U.; Vo, C.-V.T.; Bode, J.W. SnAP reagents for the synthesis of piperazines and morpholines. Org. Lett. 2014, 16, 1236–1239. [Google Scholar] [CrossRef] [PubMed]
  43. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Available online: http://agris.fao.org/agris-search/search.do?recordID = US201300683461 (accessed on 2 August 2018).
  44. Mauro, N.; Schillaci, D.; Varvarà, P.; Cusimano, M.G.; Geraci, D.M.; Giuffrè, M.; Cavallaro, G.; Maida, C.M.; Giammona, G. Branched high molecular weight glycopolypeptide with broad-spectrum antimicrobial activity for the treatment of biofilm related infections. ACS Appl. Mater. Interfaces 2018, 10, 318–331. [Google Scholar] [CrossRef] [PubMed]
Marinedrugs 16 00274 sch001 550
Scheme 1. Synthesis of new thiazoles 1i–p. Reagents: (i) (a) CSI, MeCN, 0 °C, 2 h; (b) DMF, 0 °C, 2 h, 90–98%; (ii) (a), NaH, DMF, 0 °C-rt, 30 min; (b) BrCH2CH2NHBoc, 60 °C, 24 h, 61–82%; (iii) P4S10, EtOH, rt, 1 h; then reflux, 24 h, 60–72%; (iv) EtOH, reflux, 30 min, 61–87%; (v) (a) TFA, DCM, reflux, 24 h; (b) aq NaHCO3, 60–91%.
Scheme 1. Synthesis of new thiazoles 1i–p. Reagents: (i) (a) CSI, MeCN, 0 °C, 2 h; (b) DMF, 0 °C, 2 h, 90–98%; (ii) (a), NaH, DMF, 0 °C-rt, 30 min; (b) BrCH2CH2NHBoc, 60 °C, 24 h, 61–82%; (iii) P4S10, EtOH, rt, 1 h; then reflux, 24 h, 60–72%; (iv) EtOH, reflux, 30 min, 61–87%; (v) (a) TFA, DCM, reflux, 24 h; (b) aq NaHCO3, 60–91%.
Marinedrugs 16 00274 sch001
Marinedrugs 16 00274 g001 550
Figure 1. Inhibition of sortase activity by sortase inhibitor 4-(hydroxymercuri)benzoic acid (red) and 1a (purple) and 2r (green) and the negative control (blue) as measured with SensoLyte® 520 Sortase A assay kit.
Figure 1. Inhibition of sortase activity by sortase inhibitor 4-(hydroxymercuri)benzoic acid (red) and 1a (purple) and 2r (green) and the negative control (blue) as measured with SensoLyte® 520 Sortase A assay kit.
Marinedrugs 16 00274 g001
Table
Table 1. New thiazole derivatives 1a–p.Marinedrugs 16 00274 i001
Table 1. New thiazole derivatives 1a–p.Marinedrugs 16 00274 i001
Compd.RR1R2Compd.RR1R2
1aHCH2CH2NHBocH1iHCH2CH2NH2H
1bHCH2CH2NHBocMe1jHCH2CH2NH2Me
1cOMeCH2CH2NHBocH1kOMeCH2CH2NH2H
1dOMeCH2CH2NHBocMe1lOMeCH2CH2NH2Me
1eBrCH2CH2NHBocH1mBrCH2CH2NH2H
1fBrCH2CH2NHBocMe1nBrCH2CH2NH2Me
1gFCH2CH2NHBocH1oFCH2CH2NH2H
1hFCH2CH2NHBocMe1pFCH2CH2NH2Me
Table
Table 2. Thiazole derivatives 2a–u [39].Marinedrugs 16 00274 i001
Table 2. Thiazole derivatives 2a–u [39].Marinedrugs 16 00274 i001
Compd.RR1R2Compd.RR1R2
2aHCH2CH2OMeH2lBrMeCH2CH2OMe
2bHCH2CH2OMeMe2mFCH2CH2OMeH
2cHCH2CH2OMeCH2CH2OMe2nFCH2CH2OMeMe
2dHMeCH2CH2OMe2oFCH2CH2OMeCH2CH2OMe
2eOMeCH2CH2OMeH2pFMeCH2CH2OMe
2fOMeCH2CH2OMeMe2qFHCH2CH2OMe
2gOMeCH2CH2OMeCH2CH2OMe2rHBocCH2CH2OMe
2hOMeMeCH2CH2OMe2sBrBocCH2CH2OMe
2iBrCH2CH2OMeH2tHHCH2CH2OMe
2jBrCH2CH2OMeMe2uBrHCH2CH2OMe
2kBrCH2CH2OMeCH2CH2OMe
Table
Table 3. Inhibition of biofilm formation, IC50 (µM).
Table 3. Inhibition of biofilm formation, IC50 (µM).
Compd.S. aureus ATCC 25923
µg/mL µM		S. aureus ATCC 6538
µg/mL µM		P. aeruginosa ATCC 15442
µg/mL µM
1a3.9 ± 0.28.4 ± 0.45.2 ± 0.311.3 ± 0.6--
1b13.8 ± 0.929.1 ± 1.919.3 ± 1.140.7 ± 2.315.6 ± 1.132.9 ± 2.3
1c7.1 ± 0.114.5 ± 0.211.6 ± 0.923.6 ± 1.8--
1d14.1 ± 1.027.9 ± 2.013.1 ± 0.526.0 ± 1.0--
1f9.3 ± 0.916.8 ± 1.66.5 ± 0.511.7 ± 0.937.2 ± 2.567.3 ± 4.5
1h36.9 ± 1.775.0 ± 3.49.3 ± 0.418.9 ± 0.813.1 ± 0.826.6 ± 1.6
1i4.7 ± 0.313.0 ± 0.89.7 ± 0.926.9 ± 2.522.7 ± 2.163.1 ± 5.8
1j32.9 ± 3.188.0 ± 8.36.2 ± 0.0916.6 ± 0.256.1 ± 3.2150.2 ± 8.6
1k23.3 ± 1.559.2 ± 3.84.8 ± 0.112.3 ± 0.34.2 ± 0.110.7 ± 0.2
1l48.7 ± 2.2120.6 ± 5.47.2 ± 0.717.8 ± 1.724.2 ± 0.859.9 ± 2.0
1m4.4 ± 0.110.0 ± 0.23.3 ± 0.087.5 ± 0.27.8 ± 0.0917.7 ± 0.2
1n20.1 ± 0.844.4 ± 1.85.4 ± 0.211.9 ± 0.44.6 ± 0.110.1 ± 0.2
1o1.5 ± 0.13.9 ± 0.36.3 ± 0.416.6 ± 1.04.5 ± 0.411.9 ± 1.1
1p0.5 ± 0.021.27 ± 0.055.2 ± 0.0813.2 ± 0.23.9 ± 0.079.9 ± 0.2
2d7.5 ± 0.219.3 ± 0.5----
2e18.6 ± 0.945.9 ± 2.225.4 ± 1.7 62.7 ± 4.220.5 ± 1.250.6 ± 3.0
2f1.2 ± 0.032.8 ± 0.0711.5 ± 0.726.7 ± 1.6--
2g7.9 ± 0.617.0 ± 1.311.1 ± 0.223.9 ± 0.417.7 ± 0.838.2 ± 1.7
2i0.79 ± 0.0091.7 ± 0.029.4 ± 0.320.7 ± 0.74.4 ± 0.089.7 ± 0.2
2j0.95 ± 0.012.03 ± 0.0211.2 ± 1.123.9 ± 2.319.1 ± 0.140.8 ± 0.2
2k2.9 ± 0.025.6 ± 0.0418.8 ± 1.536.7 ± 2.9--
2l2.5 ± 0.025.3 ± 0.04----
2m13.8 ± 0.735.1 ± 1.80.3 ± 0.0020.7 ± 0.005--
2n0.2 ± 0.0060.4 ± 0.01221.0 ± 1.751.6 ± 4.2--
2o28.5 ± 1.963.2 ± 4.2----
2q13.7 ± 1.134.9 ± 2.823.1 ± 1.958.8 ± 4.8--
2r1.8 ± 0.13.7 ± 0.26.9 ± 0.114.5 ± 0.2--
2t12.9 ± 0.534.4 ± 1.37.5 ± 0.620.0 ± 1.616.3 ± 1.343.5 ± 3.5
2u13.1 ± 0.828.8 ± 1.79.6 ± 0.921.1 ± 2.0--

Share and Cite

MDPI and ACS Style

Carbone, A.; Parrino, B.; Cusimano, M.G.; Spanò, V.; Montalbano, A.; Barraja, P.; Schillaci, D.; Cirrincione, G.; Diana, P.; Cascioferro, S. New Thiazole Nortopsentin Analogues Inhibit Bacterial Biofilm Formation. Mar. Drugs 2018, 16, 274. https://doi.org/10.3390/md16080274

AMA Style

Carbone A, Parrino B, Cusimano MG, Spanò V, Montalbano A, Barraja P, Schillaci D, Cirrincione G, Diana P, Cascioferro S. New Thiazole Nortopsentin Analogues Inhibit Bacterial Biofilm Formation. Marine Drugs. 2018; 16(8):274. https://doi.org/10.3390/md16080274

Chicago/Turabian Style

Carbone, Anna, Barbara Parrino, Maria Grazia Cusimano, Virginia Spanò, Alessandra Montalbano, Paola Barraja, Domenico Schillaci, Girolamo Cirrincione, Patrizia Diana, and Stella Cascioferro. 2018. "New Thiazole Nortopsentin Analogues Inhibit Bacterial Biofilm Formation" Marine Drugs 16, no. 8: 274. https://doi.org/10.3390/md16080274

APA Style

Carbone, A., Parrino, B., Cusimano, M. G., Spanò, V., Montalbano, A., Barraja, P., Schillaci, D., Cirrincione, G., Diana, P., & Cascioferro, S. (2018). New Thiazole Nortopsentin Analogues Inhibit Bacterial Biofilm Formation. Marine Drugs, 16(8), 274. https://doi.org/10.3390/md16080274

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop